Coherus Oncology (CHRS)
Commercializes LOQTORZI while advancing mid-stage immuno-oncology antibodies.
Something off on this page? Send us feedback.
Commercializes LOQTORZI for nasopharyngeal carcinoma and advances two mid-stage immuno-oncology antibodies. The business now centers on U.S. oncology sales, specialty-wholesale distribution, and clinical combinations after exiting its biosimilar franchises.
Commercializes LOQTORZI, a PD-1 inhibitor developed with Junshi Biosciences, for recurrent or metastatic nasopharyngeal carcinoma. Operations are primarily U.S.-based, with sales moving through specialty wholesalers and Puerto Rico included in distribution.
Advances casdozokitug, an IL-27 antagonist, and tagmokitug, an anti-CCR8 antibody, as mid-stage immuno-oncology candidates across liver, colorectal, head and neck, gastric, esophageal, and prostate cancer settings. The Surface Oncology acquisition brought these antibody programs into the current pipeline.
Carries a founder-led operating model after the UDENYCA sale and the exit from UDENYCA, YUSIMRY, and CIMERLI biosimilars. The business depends on LOQTORZI uptake, access through McKesson, Cencora, and Cardinal Health, clinical readouts, and funding the oncology pipeline after the biosimilar divestitures.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 4, 2025 | Maxim Group | Upgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $105.3M · Total debt $37.7M · Total assets $191.2M · Shareholders' equity $60.8M
- Revenue
- $14.3M
- Operating income
- −$32.3M
- Net income
- −$20.6M
No dividends on record.
| Institutions | ≈ 46.15% | 71.30M shares | |
|---|---|---|---|
| 152 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 0.95% | 1.47M shares | |
| 10 holders · as of Jun 9, 2026 | |||
| Other | ≈ 52.90% | 81.73M shares | |
| remainder | |||
154.50M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Timothy G. Youngquist 2020 Irrevocable TrustInstitution | 8.45% | 13.05M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 7.77% | 12.00M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 3.85% | 5.95M | as of Jun 30, 2026 |
Geode Capital Management, LLCInstitution | 2.39% | 3.69M | as of Jun 30, 2026 |
Samsara Biocapital, LLCInstitution | 2.22% | 3.43M | as of Jun 30, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- Merck
Dominant KEYTRUDA franchise across PD-1 oncology
- Bristol-Myers Squibb
OPDIVO franchise plus anti-CCR8 pipeline overlap
- AstraZeneca (ADR)
IMFINZI/IMJUDO pressure in HCC and PD-L1 IO
- BeOne Medicines (ADR)
TEVIMBRA adds another global PD-1 oncology franchise
- Regeneron
LIBTAYO adds PD-1 pressure in solid tumors
- GSK (ADR)
JEMPERLI is an additional approved PD-1 rival
- Gilead Sciences
GS-1811 creates direct anti-CCR8 pipeline overlap
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Coherus Oncology | $1.29 | −0.64% | $211.7M | — | — | 4.2 | +39.5% |
| Merck | $151.92 | +0.67% | $369.24B | 119.6 | 17.5 | 5.6 | +5.1% |
| Bristol-Myers Squibb | $62.25 | +0.01% | $127.91B | 13.8 | 9.7 | 2.6 | +5.7% |
| AstraZeneca (ADR) | $168.07 | −0.18% | $260.70B | 25.2 | 15.8 | 4.2 | +6.4% |
| BeOne Medicines (ADR) | $368.08 | +0.04% | $39.07B | 5.1 | 46.6 | 6.4 | +29.6% |
| Regeneron | $803.90 | −0.02% | $82.23B | 19.7 | 13.3 | 5.3 | +16.7% |
| GSK (ADR) | $50.70 | −0.06% | $102.34B | 16.1 | 9.3 | 2.3 | +5.3% |
| Gilead Sciences | $152.67 | 0.00% | $186.93B | — | 16.8 | 6.1 | +10.2% |
| Median | 17.9 | 15.8 | 5.3 | +6.4% |